HGF诱导NSCLC细胞对吉非替尼耐药机制的研究
|
摘要
吉非替尼是一种靶向抑制表皮生长因子受体(Epidermel Growth Factor Receptor, EGFR)的抗癌药物,为临床上应用的小分子EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI),可以靶向抑制非小细胞肺癌(non-small lung cancer, NSCLC)表达的EGFR,在治疗NSCLC的临床实践中取得了较满意的疗效。由于吉非替尼对特殊患者的选择性,实际上少部分NSCLC患者对吉非替尼有明显的疗效,大部分患者则无效或疗效差。吉非替尼敏感的患者主要是存在EGFR基因的突变,但EGFR基因突变的患者中不一定都对吉非替尼敏感。这是由于约25%-30%的EGFR基因突变者对吉非替尼原发性或获得性耐药,这种EGFR基因突变型患者对吉非替尼的耐药机制不十分清楚。
肝细胞生长因子(hepatocyte growth factor, HGF)是一种由间质细胞分泌的多功能因子,在体外促进多种细胞增殖和运动。部分肿瘤组织能表达HGF,与肿瘤细胞增殖、转移、侵袭有关。新近研究显示,肺癌组织中肿瘤编码基因MET扩增与对吉非替尼获得性耐药有关。有报道HGF诱导乳腺癌细胞对抗吉非替尼的生长抑制作用。对吉非替尼耐药的NSCLC细胞的EGFR基因型分两类,分别为EGFR突变型和EGFR野生型。我们选择了不存在EGFRT970M突变或MET扩增或KRAS突变等吉非替尼耐药相关因素,而且对吉非替尼敏感的NSCLC细胞EGFR突变型PC-9和EGFR野生型H292进行了研究。这两株细胞不存在EGFRT970M突变或MET扩增或KRAS突变等吉非替尼耐药相关因素。用HGF诱导这两株细胞,通过检测细胞增殖、周期及凋亡,观察是否对吉非替尼耐药,以及通过免疫印迹检测EGFR蛋白及MET编码的HGF的受体蛋白的表达,研究吉非替尼对非小细胞肺癌耐药的另一个途径的耐药机制,证实HGF/c-Met系统可作为治疗吉非替尼耐药的NSCLC的靶向位点,为临床提供吉非替尼联合c-Met抑制剂或HGF拮抗剂可能有效治疗耐药的NSCLC的理论依据。
MTT法检测PC-9和H292细胞增殖,作图法计算出药物半数抑制浓度(IC50); MTT法检测HGF诱导的PC-9和H292细胞增殖,利用exel文档画出药物浓度-生长曲线；实验分为4组：对照组(O)、肝细胞生长因子组(H)、吉非替尼组(G)、肝细胞生长因子+吉非替尼组(HG)。MTT法检测四组细胞存活率；细胞凋亡试剂盒(Annexin V/PE)染色和细胞周期试剂盒(PI)染色,利用流式细胞仪检测细胞凋亡和周期以及最后利用Multicycler 3.0软件分析细胞周期；比色法(Bradford法)为蛋白定量,利用蛋白质免疫印迹(Western bloting)技术检测细胞中c-Met、p-Met、p-EGFR蛋白的表达。
通过上述方法得到如下实验结果：
1、PC-9和H292均为吉非替尼敏感株,IC50分别为0.05±0.01μmol/L和0.17±0.05μmol/L。吉非替尼对PC-9和H292的生长抑制作用呈浓度依赖性,HGF (40ng/ml)诱导的吉非替尼浓度-存活率曲线均往右移,以H292的表现最为明显;
2、HGF(20ng/ml或40ng/ml)没有促进PC-9和H292增殖,但HGF(40ng/ml)和吉非替尼处理组(HG)与单纯吉非替尼处理组(G)相比有更高的存活率(P<0.05),而且低浓度的HGF(20ng/ml)也能明显提高细胞的存活率(P<0.05)；
3、HGF (20ng/ml或40ng/ml)没有降低PC-9的凋亡率,而且吉非替尼促进HGF诱导(HG)的凋亡率与单用吉非替尼(G)比较没有差异(P>0.05)。HGF (20ng/ml)能促进PC-9和H292的有丝分裂,但吉非替尼阻滞HGF诱导(HG)的G1期细胞周期比例与单用吉非替尼(G)比较没有差异(P>0.05)；
4、HGF (40ng/ml)诱导PC-9和H292增加表达c-Met的磷酸化。吉非替尼处理HGF (40ng/ml)诱导的PC-9和H292,H292有明显的p-Met的表达。吉非替尼能明显抑制HGF (40ng/ml)诱导PC-9增加表达的p-Met,但不能抑制HGF(40ng/ml)诱导H292增加表达的p-Met;
5、HGF (40ng/ml)诱导PC-9和H292增加表达EGFR的磷酸化。吉非替尼处理HGF (40ng/ml)诱导的PC-9和H292,H292仍有p-EGFR的表达,而PC-9没有p-EGFR的表达。吉非替尼能抑制HGF (40ng/ml)诱导PC-9增加表达的p-EGFR,但不能完全抑制HGF (40ng/ml)诱导H292增加表达的p-EGFR。
提示：
1、HGF可诱导敏感肺癌细胞PC-9和H292对吉非替尼耐药；
2、HGF诱导细胞凋亡及细胞周期影响可能与HGF诱导吉非替尼耐药无关；
3、HGF诱导PC-9和H292表达c-Met磷酸化和反式激活EGFR的磷酸化,可能是敏感肺癌细胞对吉非替尼耐药的重要机制；
4、吉非替尼能抑制HGF诱导EGFR突变型细胞表达的c-Met的磷酸化,不能抑制HGF诱导EGFR野生型细胞表达的c-Met的磷酸化。吉非替尼抑制HGF诱导c-Met的磷酸化可能与肺癌细胞基因类型相关；
5、吉非替尼完全抑制HGF诱导EGFR突变型细胞EGFR的磷酸化,不完全抑制EGFR野生型细胞EGFR的磷酸化。吉非替尼抑制HGF诱导EGFR的磷酸化可能与肺癌细胞基因类型有一定相关性；
6、HGF主要通过激活c-Met磷酸化诱导耐药,所以HGF/c-Met系统可作为治疗吉非替尼耐药的NSCLC的重要靶向位点；
7、HGF诱导c-Met磷酸化可能与吉非替尼原发性耐药相关,对EGFR突变的细胞来说吉非替尼能够阻断HGF诱导的EGFR和c-Met的磷酸化,所以同时应用HGF拮抗剂可能效果更佳；而对EGFR野生型的细胞来说吉非替尼不能阻断HGF诱导的c-Met的磷酸化,所以最好同时应用c-Met抑制剂或HGF拮抗剂可能带来更好的治疗效果,这为临床指导治疗NSCLC提供理论参考。
Lung cancer is one of the most prevalen tmalignancies and theleading cause of cancer-related death worldwide.Non-small-cell lung cancer (NSCLC) accounts for nearly 80% of lung cancer cases.The median survival of metastatic NSCLC is 8-10months when treated with the most active combination of conventional chemotherapeutic agents.Recent therapeutic strategies for NSCLC have focused on the development of molecular targeted therapies.Epidermal growth factor receptor (EGFR) is a member of a family of closely related growth factor receptor tyrosine kinases.As EGFR is expressed in the majority of cases of EGFR is an attractive target for the development of therapeutic agents.The small-molecule EGFR tyrosine kinase inhibitors (gefitinib) have been evaluated in clinical trials for patients with NSCLC.
Gefitinib is a antitumour drug which targeted EGFR, is small molecular EGFR tyrosine kinase inhibitor(TKI.), sensitive patients with gefitinib was EGFR-activating mutation，It has satisfactory therapeutic effects in clinical practice with treatment patients of non-small lung cancer (NSCLC). lung cancer with epidermal growth factor receptor (EGFR)-activating mutations responds favorably to the EGFR tyrosin kinase inhibitors gefitinib. However, not all the patients with EGFR-activating mutation was sure to sensitive to gefitinib,25%-30% of patients with EGFR-activating mutations show intrinsic resistance,and the responders invariably acquire resistance to gefitinib.
To overcome the intrinsic and acquired resistance to EGFR tyrosine kinase inhibitors,it is necessary to clarify the molecular mechanisms of the resistance.The mechanism of gefitinib resistance of these patients with EGFR-activating mutation is not cleared.Recently,amplificationof MET proto-oncogene,which contribute to acquired resistance to EGFR tyrosine kinase inhibitors have been reported. On the otherhand,MET amplification has been shown to restore the phosphatidylinositol. MET amplification are found in 20%-50% of patients acquiring resistance to EGFR tyrosine kinase inhibitors.However,the mechanis of intrinsic resistance and acquired resistance are still unknown.The MET gene encodes a high-affinity receptor for hepatocyte growth factor.originally,cloned as a mitogenic protein for hepatocytes, specifically activates MET receptor tyrosine kinase and induces pleiotropic biological effects in a wide variety of cells, including mitogenic, motogenic, mophogenic, and anti apoptotic activities。Hepatocyte growth factor (HGF) is a multifunctional agent from stromal secrete which promote proliferation and movement of multy cells in vitro.Tthe document reported tissue of lung cancer can secret HGF and HGF can promote proliferation and metastasis and invasion of tumor cells. As HGF expressed in lung cancer cells and stromal cells,we investigated Whether HGF is involved in gefitinib resistance of lung adenocacinoma cells with EGFR-activating mutations.
commonly,there ware two kinds of cells to gefitinb-resistance, respectively EGFR-activating mutation and EGFR-wild type.we selected PC-9 with EGFR-activating mutation and H292 with wild type EGFR, these cells don't have relative factors of EGFR-T970M mutation or MET amplification or KRAS-activating mutation et al. we induced two cells with hepatocyte growth factor (HGF) and observed cell activity、cell apoptosis、cell cycle, express of EGFR protein and HGF-receptor protein of encoded by MET, research the other one-mechanism of gefitinib-resistance in NSCLC. it may confirm the systerm of HGF/c-Met as important target site to therapy NSCLC, provide rationale basis to possibly treat NSCLC of gefitinib-resistance in clinically by combination with c-Met inhibitor or HGF antagon explore mechanism of gefitinib resistance by examine expression of proteins.
The proliferation of PC-9 and H292 cells was mesured by MTT assay, and IC50 of drug was calculated by graphic method; the proliferation of PC-9 and H292 cells was mesured by MTT assay and the curve of drug concentration-growth in exel document were painted.PC-9 and H292 cells were devided into 4 group,controul group, hepatocyte growth factor (HGF) group, gfitinib group and combine group (HGF+gefitinib).The survival of four cell's group was mesured by MTT assay; the cells stain by Annexin V-PE Apoptosis Detection Kit and Flow Cytometry Analysis Of Cell Kit, cell cycle distribution and apoptosis by flow cytometry, finally analyses of cell cycle by Multicycler 3.0 soft; quantitate the protein by Bradford method.The expression of c-Met、p-Met、p-EGFR protein were examined by western blotting.
Get the as follows that experimental result by said methods:
1. Both PC-9 and H292 cells were sensitive to gefitinib,the IC50 is 0.05±0.01μmol/L and 0.17±0.05μmol/L, respectively. gefitinib inhibited cell growth of PC-9 and H292 in a dose-dependent manner, both the inhibition ratio-concentration curve of gefitinib shifts right when induced with HGF (40ng/ml)
2. HGF did not affect proliferation of PC-9 and H292 cells,higher rate of survival was present when treated with HGF (40ng/ml) and gefitinib than treated with gefitinib alone (P＜0.05);In addition,low concentration of HGF (20ng/ml) could enhance rate of survival (P＜0.05)
3. HGF (40ng/m,20ng/ml) alone had no effect on induction of apoptosis of PC-9 cells and the rate of apoptosis showed no diferrence between HG group (40ng/m,20ng/ml) and G group (P>0.05).Gefitinib HGF (20ng/ml) alone could enhanced mitosis of PC-9 and H292 cells. However, the ratio of inhibing cell cycle (G1 phase) showed no diferrence between HG group and G group (P>0.05)
4. HGF (40ng/ml) stimulated phosphorylation of Met in PC-9. In the presence of gefitinib,HGF slitely restored phosphorylation of Met in PC-9; HGF (40ng/ml) stimulated phosphorylation of EGFR in H292.Even in the presence of gefitinib, HGF evidently restored phosphorylation of EGFR in H292;
5. HGF (40ng/ml) stimulated phosphorylation of Met in PC-9 and H292. In the presence of gefitinib,HGF slitely restored phosphorylation of EGFR in H292.
Hint:
1. HGF induced gefitinib resistance of PC-9 with EGFR-activating mutation and H292 cells with EGFR-wild type;
2. Cell apoptosis and cell cycle effection induced by HGF cell might not be related with the gefitinib resistance of of NSCLC with EGFR-activating mutation or with EGFR-wild type;
3. HGF induced PC-9 and H292 cells enhancing phosphorylation of EGFR and Met,which may be inportent mechanism of gefitinib resistance.of of NSCLC with EGFR-activating mutation or with EGFR-wild type;
4. HGF-induced phosphorylation of c-Met was inhibited by gefitinib in mutant EGFR cell line, but not down-regulated by gefitinib in wild type EGFR cell line. It might be related with EGFR gene type of NSCLC that gefitinib inhibited HGF-induced phosphorylation of c-Met;
5. HGF-induced phosphorylation of EGFR was inhibited by gefitinib in mutant EGFR cell line, but not completely down-regulated by gefitinib in wild type EGFR cell line.It might be related with EGFR gene type of NSCLC that gefitinib inhibited HGF-induced phosphorylation of EGFR;
6. HGF induced gefitinib resistance by activating phosphorylation of c-Met mainly, so systerm of HGF/c-Met might be target sites of treating NSCLC with EGFR;
7. HGF-induced phosphorylation of c-Met is related with gefitinib-resistance, HGF-induced phosphorylation of c-Met was evidently inhibited by gefitinib in mutant EGFR cell line, so gefitinib combining with HGF antagonist may be more effective in treating NSCLC with mutant EGFR; but HGF-induced phosphorylation of c-Met wasn't inhibited byefitinib in wild type EGFR cell line, so gefitinib combining with c-Met inhibitor may be more effective in treating NSCLC with wild type EGFR.These provide rationale reference to guide therapy of NSCLC in clinically.
肝细胞生长因子(hepatocyte growth factor, HGF)是一种由间质细胞分泌的多功能因子,在体外促进多种细胞增殖和运动。部分肿瘤组织能表达HGF,与肿瘤细胞增殖、转移、侵袭有关。新近研究显示,肺癌组织中肿瘤编码基因MET扩增与对吉非替尼获得性耐药有关。有报道HGF诱导乳腺癌细胞对抗吉非替尼的生长抑制作用。对吉非替尼耐药的NSCLC细胞的EGFR基因型分两类,分别为EGFR突变型和EGFR野生型。我们选择了不存在EGFRT970M突变或MET扩增或KRAS突变等吉非替尼耐药相关因素,而且对吉非替尼敏感的NSCLC细胞EGFR突变型PC-9和EGFR野生型H292进行了研究。这两株细胞不存在EGFRT970M突变或MET扩增或KRAS突变等吉非替尼耐药相关因素。用HGF诱导这两株细胞,通过检测细胞增殖、周期及凋亡,观察是否对吉非替尼耐药,以及通过免疫印迹检测EGFR蛋白及MET编码的HGF的受体蛋白的表达,研究吉非替尼对非小细胞肺癌耐药的另一个途径的耐药机制,证实HGF/c-Met系统可作为治疗吉非替尼耐药的NSCLC的靶向位点,为临床提供吉非替尼联合c-Met抑制剂或HGF拮抗剂可能有效治疗耐药的NSCLC的理论依据。
MTT法检测PC-9和H292细胞增殖,作图法计算出药物半数抑制浓度(IC50); MTT法检测HGF诱导的PC-9和H292细胞增殖,利用exel文档画出药物浓度-生长曲线；实验分为4组：对照组(O)、肝细胞生长因子组(H)、吉非替尼组(G)、肝细胞生长因子+吉非替尼组(HG)。MTT法检测四组细胞存活率；细胞凋亡试剂盒(Annexin V/PE)染色和细胞周期试剂盒(PI)染色,利用流式细胞仪检测细胞凋亡和周期以及最后利用Multicycler 3.0软件分析细胞周期；比色法(Bradford法)为蛋白定量,利用蛋白质免疫印迹(Western bloting)技术检测细胞中c-Met、p-Met、p-EGFR蛋白的表达。
通过上述方法得到如下实验结果：
1、PC-9和H292均为吉非替尼敏感株,IC50分别为0.05±0.01μmol/L和0.17±0.05μmol/L。吉非替尼对PC-9和H292的生长抑制作用呈浓度依赖性,HGF (40ng/ml)诱导的吉非替尼浓度-存活率曲线均往右移,以H292的表现最为明显;
2、HGF(20ng/ml或40ng/ml)没有促进PC-9和H292增殖,但HGF(40ng/ml)和吉非替尼处理组(HG)与单纯吉非替尼处理组(G)相比有更高的存活率(P<0.05),而且低浓度的HGF(20ng/ml)也能明显提高细胞的存活率(P<0.05)；
3、HGF (20ng/ml或40ng/ml)没有降低PC-9的凋亡率,而且吉非替尼促进HGF诱导(HG)的凋亡率与单用吉非替尼(G)比较没有差异(P>0.05)。HGF (20ng/ml)能促进PC-9和H292的有丝分裂,但吉非替尼阻滞HGF诱导(HG)的G1期细胞周期比例与单用吉非替尼(G)比较没有差异(P>0.05)；
4、HGF (40ng/ml)诱导PC-9和H292增加表达c-Met的磷酸化。吉非替尼处理HGF (40ng/ml)诱导的PC-9和H292,H292有明显的p-Met的表达。吉非替尼能明显抑制HGF (40ng/ml)诱导PC-9增加表达的p-Met,但不能抑制HGF(40ng/ml)诱导H292增加表达的p-Met;
5、HGF (40ng/ml)诱导PC-9和H292增加表达EGFR的磷酸化。吉非替尼处理HGF (40ng/ml)诱导的PC-9和H292,H292仍有p-EGFR的表达,而PC-9没有p-EGFR的表达。吉非替尼能抑制HGF (40ng/ml)诱导PC-9增加表达的p-EGFR,但不能完全抑制HGF (40ng/ml)诱导H292增加表达的p-EGFR。
提示：
1、HGF可诱导敏感肺癌细胞PC-9和H292对吉非替尼耐药；
2、HGF诱导细胞凋亡及细胞周期影响可能与HGF诱导吉非替尼耐药无关；
3、HGF诱导PC-9和H292表达c-Met磷酸化和反式激活EGFR的磷酸化,可能是敏感肺癌细胞对吉非替尼耐药的重要机制；
4、吉非替尼能抑制HGF诱导EGFR突变型细胞表达的c-Met的磷酸化,不能抑制HGF诱导EGFR野生型细胞表达的c-Met的磷酸化。吉非替尼抑制HGF诱导c-Met的磷酸化可能与肺癌细胞基因类型相关；
5、吉非替尼完全抑制HGF诱导EGFR突变型细胞EGFR的磷酸化,不完全抑制EGFR野生型细胞EGFR的磷酸化。吉非替尼抑制HGF诱导EGFR的磷酸化可能与肺癌细胞基因类型有一定相关性；
6、HGF主要通过激活c-Met磷酸化诱导耐药,所以HGF/c-Met系统可作为治疗吉非替尼耐药的NSCLC的重要靶向位点；
7、HGF诱导c-Met磷酸化可能与吉非替尼原发性耐药相关,对EGFR突变的细胞来说吉非替尼能够阻断HGF诱导的EGFR和c-Met的磷酸化,所以同时应用HGF拮抗剂可能效果更佳；而对EGFR野生型的细胞来说吉非替尼不能阻断HGF诱导的c-Met的磷酸化,所以最好同时应用c-Met抑制剂或HGF拮抗剂可能带来更好的治疗效果,这为临床指导治疗NSCLC提供理论参考。
Lung cancer is one of the most prevalen tmalignancies and theleading cause of cancer-related death worldwide.Non-small-cell lung cancer (NSCLC) accounts for nearly 80% of lung cancer cases.The median survival of metastatic NSCLC is 8-10months when treated with the most active combination of conventional chemotherapeutic agents.Recent therapeutic strategies for NSCLC have focused on the development of molecular targeted therapies.Epidermal growth factor receptor (EGFR) is a member of a family of closely related growth factor receptor tyrosine kinases.As EGFR is expressed in the majority of cases of EGFR is an attractive target for the development of therapeutic agents.The small-molecule EGFR tyrosine kinase inhibitors (gefitinib) have been evaluated in clinical trials for patients with NSCLC.
Gefitinib is a antitumour drug which targeted EGFR, is small molecular EGFR tyrosine kinase inhibitor(TKI.), sensitive patients with gefitinib was EGFR-activating mutation，It has satisfactory therapeutic effects in clinical practice with treatment patients of non-small lung cancer (NSCLC). lung cancer with epidermal growth factor receptor (EGFR)-activating mutations responds favorably to the EGFR tyrosin kinase inhibitors gefitinib. However, not all the patients with EGFR-activating mutation was sure to sensitive to gefitinib,25%-30% of patients with EGFR-activating mutations show intrinsic resistance,and the responders invariably acquire resistance to gefitinib.
To overcome the intrinsic and acquired resistance to EGFR tyrosine kinase inhibitors,it is necessary to clarify the molecular mechanisms of the resistance.The mechanism of gefitinib resistance of these patients with EGFR-activating mutation is not cleared.Recently,amplificationof MET proto-oncogene,which contribute to acquired resistance to EGFR tyrosine kinase inhibitors have been reported. On the otherhand,MET amplification has been shown to restore the phosphatidylinositol. MET amplification are found in 20%-50% of patients acquiring resistance to EGFR tyrosine kinase inhibitors.However,the mechanis of intrinsic resistance and acquired resistance are still unknown.The MET gene encodes a high-affinity receptor for hepatocyte growth factor.originally,cloned as a mitogenic protein for hepatocytes, specifically activates MET receptor tyrosine kinase and induces pleiotropic biological effects in a wide variety of cells, including mitogenic, motogenic, mophogenic, and anti apoptotic activities。Hepatocyte growth factor (HGF) is a multifunctional agent from stromal secrete which promote proliferation and movement of multy cells in vitro.Tthe document reported tissue of lung cancer can secret HGF and HGF can promote proliferation and metastasis and invasion of tumor cells. As HGF expressed in lung cancer cells and stromal cells,we investigated Whether HGF is involved in gefitinib resistance of lung adenocacinoma cells with EGFR-activating mutations.
commonly,there ware two kinds of cells to gefitinb-resistance, respectively EGFR-activating mutation and EGFR-wild type.we selected PC-9 with EGFR-activating mutation and H292 with wild type EGFR, these cells don't have relative factors of EGFR-T970M mutation or MET amplification or KRAS-activating mutation et al. we induced two cells with hepatocyte growth factor (HGF) and observed cell activity、cell apoptosis、cell cycle, express of EGFR protein and HGF-receptor protein of encoded by MET, research the other one-mechanism of gefitinib-resistance in NSCLC. it may confirm the systerm of HGF/c-Met as important target site to therapy NSCLC, provide rationale basis to possibly treat NSCLC of gefitinib-resistance in clinically by combination with c-Met inhibitor or HGF antagon explore mechanism of gefitinib resistance by examine expression of proteins.
The proliferation of PC-9 and H292 cells was mesured by MTT assay, and IC50 of drug was calculated by graphic method; the proliferation of PC-9 and H292 cells was mesured by MTT assay and the curve of drug concentration-growth in exel document were painted.PC-9 and H292 cells were devided into 4 group,controul group, hepatocyte growth factor (HGF) group, gfitinib group and combine group (HGF+gefitinib).The survival of four cell's group was mesured by MTT assay; the cells stain by Annexin V-PE Apoptosis Detection Kit and Flow Cytometry Analysis Of Cell Kit, cell cycle distribution and apoptosis by flow cytometry, finally analyses of cell cycle by Multicycler 3.0 soft; quantitate the protein by Bradford method.The expression of c-Met、p-Met、p-EGFR protein were examined by western blotting.
Get the as follows that experimental result by said methods:
1. Both PC-9 and H292 cells were sensitive to gefitinib,the IC50 is 0.05±0.01μmol/L and 0.17±0.05μmol/L, respectively. gefitinib inhibited cell growth of PC-9 and H292 in a dose-dependent manner, both the inhibition ratio-concentration curve of gefitinib shifts right when induced with HGF (40ng/ml)
2. HGF did not affect proliferation of PC-9 and H292 cells,higher rate of survival was present when treated with HGF (40ng/ml) and gefitinib than treated with gefitinib alone (P＜0.05);In addition,low concentration of HGF (20ng/ml) could enhance rate of survival (P＜0.05)
3. HGF (40ng/m,20ng/ml) alone had no effect on induction of apoptosis of PC-9 cells and the rate of apoptosis showed no diferrence between HG group (40ng/m,20ng/ml) and G group (P>0.05).Gefitinib HGF (20ng/ml) alone could enhanced mitosis of PC-9 and H292 cells. However, the ratio of inhibing cell cycle (G1 phase) showed no diferrence between HG group and G group (P>0.05)
4. HGF (40ng/ml) stimulated phosphorylation of Met in PC-9. In the presence of gefitinib,HGF slitely restored phosphorylation of Met in PC-9; HGF (40ng/ml) stimulated phosphorylation of EGFR in H292.Even in the presence of gefitinib, HGF evidently restored phosphorylation of EGFR in H292;
5. HGF (40ng/ml) stimulated phosphorylation of Met in PC-9 and H292. In the presence of gefitinib,HGF slitely restored phosphorylation of EGFR in H292.
Hint:
1. HGF induced gefitinib resistance of PC-9 with EGFR-activating mutation and H292 cells with EGFR-wild type;
2. Cell apoptosis and cell cycle effection induced by HGF cell might not be related with the gefitinib resistance of of NSCLC with EGFR-activating mutation or with EGFR-wild type;
3. HGF induced PC-9 and H292 cells enhancing phosphorylation of EGFR and Met,which may be inportent mechanism of gefitinib resistance.of of NSCLC with EGFR-activating mutation or with EGFR-wild type;
4. HGF-induced phosphorylation of c-Met was inhibited by gefitinib in mutant EGFR cell line, but not down-regulated by gefitinib in wild type EGFR cell line. It might be related with EGFR gene type of NSCLC that gefitinib inhibited HGF-induced phosphorylation of c-Met;
5. HGF-induced phosphorylation of EGFR was inhibited by gefitinib in mutant EGFR cell line, but not completely down-regulated by gefitinib in wild type EGFR cell line.It might be related with EGFR gene type of NSCLC that gefitinib inhibited HGF-induced phosphorylation of EGFR;
6. HGF induced gefitinib resistance by activating phosphorylation of c-Met mainly, so systerm of HGF/c-Met might be target sites of treating NSCLC with EGFR;
7. HGF-induced phosphorylation of c-Met is related with gefitinib-resistance, HGF-induced phosphorylation of c-Met was evidently inhibited by gefitinib in mutant EGFR cell line, so gefitinib combining with HGF antagonist may be more effective in treating NSCLC with mutant EGFR; but HGF-induced phosphorylation of c-Met wasn't inhibited byefitinib in wild type EGFR cell line, so gefitinib combining with c-Met inhibitor may be more effective in treating NSCLC with wild type EGFR.These provide rationale reference to guide therapy of NSCLC in clinically.
引文
[1]Bunn PA Jr,Kelly K.New chemotherapeutic agents prolong survival and improve quality of life in non-smll cell lung cancer:a review of the literature and futrre directions.Clin Cancer Res.1998;4 (5):1087-1100.
[2]Scagliotti GV,Selvaggi QNovello S,Hirsch FR.The biology of epidermal growth factor recptor in lung cancer.Clin Cancer Res.2004;10 (12 Pt 2):4227s-4232s.
[3]Yarden Y,Sliwkouski MX.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol.2001;2 (2):127-137.
[4]Schlessinger J.Cell signaling by receptor tyrosine kinases.Cell.2000; 103 (2) 211-225.
[5]Mendelsohn J,Baselga J.The EGF receptor family as targets for cancer therapy.Oncogene.2000; 19 (56):6550-6565.
[6]Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis.Eur JCancer.2001;37 (Suppl 4):S9-S15.
[7]Salomon DS,Brandt R,Ciardiello F,Normanno N.Epidermal growth factor-related peptides and their receptors in human malignancies.Crit Rev Oncol Hemaol.1995;19 (3):183-232.
[8]Ennis BW,Lippman ME,Dickson RB.The EGF receptor system as a target for antitumor therapy.Cancer Invest.1991;9 (5):553-562.
[9]朱岩,张晓彤,李龙芸.EGFR酪氨酸激酶域基因变异及相关蛋白表达与gefitinib治疗晚期非小细胞肺癌疗效相关性的研究进展.肺癌进展杂志,2006,4(2)：147-151.
[10]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) J Clin Oncol.2003;21 (12):2237-2246.
[11]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidetmal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Cancer Sci.2007;98 (12):1817-1824.
[12]张力.NCCN一线治疗引出的思考.中国肺癌杂志,2009,12(6)：611-614.
[13]Lynch TJ,Bel DW,Serdela R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N En J Med.2004;350 (21):2129.
[14]Paez JG,Janne PA,Tee JC,et al.EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy. Science 2004;304 (5676):1497.
[15]Pao W,Miller VA,Politi KA,et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PloS Med.2005;2 (3):e73.
[16]Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small cell lung cancer to gefitinib.N Engl J Med.2005;352 (8):786-792.
[17]Bean J,Brennan C,Shih JY,et al.MET amplification occurs with or without T790M mutation in EGFR mutation lung tumors with acquired resistance to gefitinib or erlotinib.PNAS.2007; 104 (52):20932-20937.
[18]Engelman JA, Zejnullahu K, Mitsudomi T, et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316 (5827):1039-1043.
[19]Pao W,Wang TY,Riely GJ, et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.PloS Med.2005;2 (1):e17.
[20]Giaccone QGallegos RM,Le CT,et al.Erlotinib for frontline treatment of advanced non-small cell lung cancer:a phase Ⅱ study.Clin Cancer Res.2006; 12 (20 Pt1):6049-6055.
[21]She QB,Solit D,Basso A,Moasser MM.Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.Clin Cancer Res.2003;9 (12):4340-4346.
[22]Balak MN,Gong Y,Riely GJ.et al.Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Clin Cancer Res.2006; 12(21):6494-6501.
[23]Rodenhuis S, van de Wetering ML, Mooi WJ,et al. Mutational activation of the KRAS oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med.1987;317 (15):929-935.
[24]Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res.1992;52 (9 Suppl):2665s-2669s.
[25]Gazdar A, Shigematsu H, Herz J, Minna J.Mutations and addiction to EGFR:The Achilles'heal'of lung cancers? Trends Mol Med.2004; 10 (10):481-486.
[26]Birchmeier C,Birchmeier W,Gherardi E,Vande Woude GF.Met,metastasis, motility and more.Nat Rev Mol Cell Biol.2003;4 (12):915-925.
[27]Trusolino L,Comoglio PM. Scatter-factor and semaphoring receptors:cell signalling for invasive growth. Nat Rev Cancer 2002;2 (4):289-300.
[28]Furge KA,Zhang YW,Vande Woude GF.Met receptor tyrosine kinase:enhanced signaling through adapter proteins.Oncogene.2000; 19 (49):5582-5589.
[29]Boccaccio C,Comoglio PM.Invasive growth:a MET driven genetic programme for cancer and stem cells. Nat Rev Cancer.2006;6 (8):637-645.
[30]Olivero M, Rizzo M, Madeddu R,et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Britsh Journal of Cancer.1996;74 (12):1862-1868.
[31]Ichimura E, Maeshima A, Nakajima T,et al.Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.Jpn J Cancer Res 1996;87 (10):1063-9.
[32]Namiki Y,Namiki T,Yoshida H,et al.Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839,Iressa) for dissemination pritoneal scirrhous gastric cancer.Int.J.Cancer.2006;118 (6) 1545-1555.
[33]Christensen JQSchreck R,Burrows J,et al.A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exibits Cytoreductive Antitumor Activity in Vivo. Cancer Res.2003;63 (21):7345-7355.
[34]Dong G,Lee TL,Yeh NT,et al.Metastatic squamou cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expressin,scattering and metastasis in response to hepatocyte growth factor.Oncogene.2004;23 (37) 6199-6208.
[35]Gao CF,Vande Woude GF..HGF/SF-Met signaling in tumor progression.Cell Research.2005;15 (1):49-51.
[36]Maulik G,Shrikhande A,Kijima T,et al.Role of the hepatocyte growth factor receptor,c-Met,in oncogenesis and potential for therapeutic inhibition.Cytokine Growth Factor Rev.2002; 13 (1):41-59.
[37]Comoglio PM,Giordano S,Trusolino L.Drug development of MET inhibitors: targeting oncogene addiction and expedience.Nat Rev Drug Discov.2008;7 (6) 504-516.
[38]高霞,刁路明,陈洪雷等.肝细胞生长因子及其受体在非小细胞肺癌中的表达及意义.实用肿瘤杂志,2005,20(1)：17-20.
[39]刘静,王岩,杨斌等.肝细胞生长因子在非小细胞肺癌中的表达及其意义.中国实验诊断学,2007,11(2)：155-158.
[40]Zucali PA,Ruiz MQGiovannetti E,et al.Role of c-met expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology.2008;19 (9):1605-1612.
[41]MoCubrey JA,Steelman LS,Chappell WH,et al.Role of the Raf/MEK/ERK pathway in cell growth,malignant,transformation and drug resistance.Biochim Biophys Acta.2007;1773 (8):1263-1284.
[42]Jiang BH,Liu LZ.PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta.2008;1784 (1):150-158.
[43]Haura EB, Zheng Z,Song L,et al. Activated Epidermal Growth Factor Receptor-STAT-3 Signaling Promotes Tumor Survival In vivo in Non-Small Cell Lung Cancer. Clin Cancer Res.2005;11 (23):8288-8294.
[44]Arteaga CL.Epidermal growth factor receptor dependence in human tumors:more than just expression? Oncologist.2002;7 (Sppl 4):31-39.
[45]Ritter CA, Arteaga CL.The epidermal growth factor receptortyrosine kinase:a promising therapeutic target in solid tumors. Semin Oncol.2003;30 (1 Suppl 1) 3-11.
[46]Ciardiello F,Caputo R,Bianco R,et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa),an epidermal growth factor receptor-selective tyrosine kinase inhibitor.Clin Cancer Res.2000;6 (5):2053-2063.
[47]Konishi J,Yamazaki K,Kinoshita I,et al.Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.Anticancer Res.2005;25 (1B):435-441.
[48]Birnbaum A,Ready N.Gefitinib therapy for non-small cell lung cancer.Curr Treat Options Oncol.2005;6 (1):75-81
[49]Mu XL,Li LY,Zhang XT,et al.Evaluation of safety and eficacy of gefitinib ('iressa',zd1839) as monotherapy in a series of Chinese patients with advanced non-small cell lung cancer:esperience from acompassionate-use programme.BMC Cancer.2004;4:51.
[50]Zhang XZ,Chang A.Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Int.J.Med.2008;5 (4):209-217.
[51]Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer:search and destroy. Eur J Cancer.2006;42 (1):17-23.
[52]Tracy S,Mukohara T,Hansen M,et al.Gefitinib Induces Apoptosis in the EGFRL858R Non-Small-Cell Lung Cancer Cell Line H3255.Cancer Res.2004;64 (20):7241-7244.
[53]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of inhibitors sensitivity in lung cancer. Cancer Sci.2007;98 (12):1817-1824.
[54]Huang SF,Liu HP,Li LH,et al.High frequency of epidermeal growth factor receptor mutations with complex patterns in non-smal cel lung cancers related to gefitinib responsiveness in Taiwan.Clin Cancer Res.2004;10 (24):8195-8203.
[55]Engelman FA,Janne PA.Mechanisms of acquired resistance to epidermal growth factor recptor tyrosine kinase inhibitors in non-small cell lung cancet.Clin Cancer Res.2008;14 (10):2895-2899.
[56]Chakravarti A,Loeffler JS,Dyson NJ.Insulin-like growth factor receptor 1 mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.Cancer Res.2002;62 (1):200-207.
[57]Jones HE,Goddard L,Gee JM,et al.Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839;Iressa) in human breast and prostate cancer cells.Endocr Relat Cancer.2004; 11 (4):793-814.
[58]EngelmanJA,MukoharaT,Zejnullahu K,et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.J Clin Invest.2006; 116 (10):2695-2706.
[59]Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib. Hum Mol Genet.2004; 13 (24) 3029-3043.
[60]Ishikawa N, Daigo Y, Takano A,et al. Increases of Amphiregulin and Transforming Growth Factor-a in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers. Cancer Res.2005; 65:(20):9176-9184. TGF-a
[61]Morgillo F, Kim WY, Kim ES,et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res.2007; 13 (9):2795-803.IGF-I
[62]Uenol Y, Sakurai H, Matsuo M,et al. Selective inhibition of TNF-a-induced activation of mitogenactivated protein kinases and metastatic activities by gefitinib. British Journal of Cancer.2005;92 (9):1690-1695.
[63]牛慧彦,李慧,何平.肝细胞生长因子对肺癌95D细胞系增殖和侵袭的影响。中国医学工程,2009,17(3)：164-166.
[64]Mueller KL,Hunter LA,Ethier SP,et al.Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells.Cancet Res.2008;68 (9):3314-3322.
[65]姜凯,黄志强.肝细胞生长因子和血管内皮细胞生长因子的生物学特性研究进展[J].肿瘤防治杂志,2003,10(1)：108-112.
[66]张保国,徐晋,姚乐申.恶性肿瘤患者血清中肝细胞生长因子定量测定的临床意义[J].实用医学杂志,2005,12(46)：41-47.
[67]Senguta S,Gherardi E,Sellers LA,et al.Hepatocyte growth factor/scater factor can induce angiogenesis independently of vascular endothelial growth factor[J].Arterioscler Thromb Vasc Biol.2003;23 (1):69-75.
[68]Wojta J,Kaun C,Breuss JM,et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest.1999;79 (4):427-438.
[69]Hynes NE,MacDonald G.ErbB receptors and signaling pathways in cancer.Current Opinion in Cell Biology.2009;21 (2):177-184.
[70]Ma PC,Tretiakova MS,Nallasura V,et al.Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer:implications for tumour invasion.British Journal of Cancer.2007;97 (3):368-377.
[71]Huether A,Hopfner M,Sutter AP,et al.Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chmosensitivity towards cytostatics.Journal of Hepatology.2005;43 (4):661-669.
[72]Chang GC, Hsu SL, Tsai JR,et al. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochemical Pharmacology.2004;68 (7):1453-1464.
[73]Walter KA,Hossain MA,Luddy C,et al.Scatter Factor/Hepatocyte Growth Factor Stimulation of Glioblastoma Cell Cycle Progression throuth G1 Is c-Myc Dependent and Independent of P27 Suppression,Cdk2 Activation, or E2F1-Dependent Transcription.Mol Cell Biol.2002;22 (8):2703-2715.
[74]Yu-hua Z,Wei W,Hao X,et al.Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinomal cells through MEK and PI3K signaling path ways. Chinese Medical Journal 2007;120 (9):743-748.
[75]Bonine-Summers AR,Aakre ME,Brown KA,et al.Epidermal Growth Factor Receptor Plays a Significant Role in Hepatocyte Growth Factor Mediated Biological Responses in Mammary Epithelial Cells.Cancer Biology & Therapy. 2007;6 (4):el-e10.
[76]董彤,辛晓燕.肝细胞生长因子及其受体在卵巢癌细胞中的表达[J].肿瘤与临床,2006,8(18)：541-543.
[77]Ma PC,Jagadeeswaran R,Jagadeesh S,et al.Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res.2005;65 (4):1479-1488.
[78]Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell.2003;3 (4) 347-361.
[79]Siegfried JM,Weissfeld LA, Singh-Kaw P,et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res.1997;57 (3):433-439.
[80]Sawada K,Radjabi AR, Shinomiya N,et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res.2007;67 (4):1670-1679.
[81]Masuya D,Huang C,Liu D,et al.The tumour-stromal interaction between intretumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients.British Journal of Cancer.2004;90 (8):1555-1562.
[82]Guo A, Villen J, Kornhauser J,et al.Signaling network assembled by oncogenic EGFR and c-Met. PNAS.2008; 105 (2):692-697.
[83]Tsao MS, Yang Y, Marcus A,et al.Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum Pathol. 2001;32 (1):57-65.
[84]Graham Carpenter. Employment of the Epidermal Growth Factor Receptor in Growth Factor-independent Signaling Pathways. The Journal of Cell Biology 1999;146 (4):697-702.
[85]Riedemann J,Sohail M,Macaulay VM.Dual silencing of the EGF and type I IGF receptors suggests dominance of IGF signaling in human breast cancer cells.Biochem Biophys Res Commun.2007;355 (3):700-706.
[86]Riedemann J,Takiguchi M,Sohil M,Macaulay VM.The EGF receptor interacts with the type I IGF receptor and regulates its stability. Biochem Biophys Res Commun2007;355 (3):707-714.
[87]Jo MJ, Stolz DB, Esplen JE,et al. Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells.THE JOURNAL OF BIOLOGICAL CHEMISTRY.2000;275 (12):8806-8811.
[88]Pai R, Nakamura T, Moon WS,et al.Prostaglandins promote colon cancer cell invasion;signaling by cross-talk between two distinct growth factor receptors. FASEB J.2003; 17 (12); 1640-1647.
[89]Reznik TE,Sang Y,Ma Y,et al.Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.Mol Cancer Res.2008;6 (1) 139-150.
[90]Puri N,Ralgia R.Synergism of EGFR and c-Met pathways,cross-talk and inhibition,in non-small cell lung cancer. Journal of Carcinogenesis.2008;7 (9):1-7.
[91]Wen J,Matsumoto K,Taniura N,et al.Inhibition of colon cancer growth and meastasis by NK4 gene repetitive delivery in mice.Biochem Biothys Res Commun.2007;358 (1):117-123.
[92]Martens T,Schmidt NO,Eckerich C,et al.A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.Clin Cancer Res 2006; 12 (20Pt 1):6144-6152.
[93]Zou HY,Li Q,Lee H,et al.An orally available small-molecule nihibitor of c-Met, PF-2341066,exhibits cytore-ductive antitumor efficacy through antiproliferative and antiangigenic mechanisms.Cancer Res.2007;67 (9):4408-4417.
[1]Bunn PA Jr,Kelly K.New chemotherapeutic agents prolong survival and improve quality of life in non-smll cell lung cancer:a review of the literature and futrre directions.Clin Cancer Res.1998;4 (5):1087-1100.
[2]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidetmal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Cancer Sci.2007;98 (12):1817-1824.
[3]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) .J Clin Oncol.2003;21 (12):2237-2246.
[4]MoCubrey JA,Steelman LS,Chappell WH,et al.Role of the Raf/MEK/ERK pathway in cell growth,malignant,transformation and drug resistance.Biochim Biophys Acta.2007;1773 (8):1263-1284.
[5]Jiang BH,Liu LZ.PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta.2008; 1784 (1):150-158.
[6]Haura EB, Zheng Z,Song LX,et al. Activated Epidermal Growth Factor Receptor-STAT-3 Signaling Promotes Tumor Survival In vivo in Non-Small Cell Lung Cancer. Clin Cancer Res 2005; 11 (23):8288-8294.
[7]Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis.Eur J Cancer.2001;37 (Suppl 4):S9-S15.
[8]Salomon DS,Brandt R,Ciardiello F,Normanno N.Epidermal growth factor-related peptides and their receptors in human malignancies.Crit Rev Oncol Hemaol.1995;19 (3):183-232.
[9]Arteaga CL.Epidermal growth factor receptor dependence in human tumors:more than just expression? Oncologist 2002;7 (14):31-39.
[10]Ciardiello F,Caputo R,Bianco R,et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa),an epidermal growth factor receptor-selective tyrosine kinase inhibitor.Clin Cancer Res.2000;6
(5):2053-2063.
[11]Konishi J,Yamazaki K,Kinoshita I,et al.Analysis of the response and toxicity to gefitinib of non-small cell lung cancer. An ticancer Res.2005;25 (1B):435-441.
[12]Birnbaum A,Ready N.Gefitinib therapy for non-small cell lung cancer.Curr Treat Options Oncol.2005;6 (1):75-81.
[13]Mu XL,Li LY,Zhang XT,et al.Evaluation of safety and eficacy of gefitinib ('iressa',zd1839) as monotherapy in a series of Chinese patients with advanced non-small cell lung cancenesperience from acompassionate-use programme.BMC Cancer.2004;4:51.
[14]朱岩,张晓彤,李龙芸.EGFR酪氨酸激酶域基因变异及相关蛋白表达与gefitinib治疗晚期非小细胞肺癌疗效相关性的研究进展.肺癌进展杂志,2006;4(2)：147-151.
[15]张力。NCCN一线治疗引出的思考.中国肺癌杂志,2009；12(6)：611-614.
[16]Lynch TJ,Bel DW,Serdela R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N En J Med.2004;350 (21):2129.
[17]Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer:search and destroy. Eur J Cancer.2006;42 (1):17-23.
[18]Tracy S,Mukohara T,Hansen M,et al.Gefitinib Induces Apoptosis in the EGFRL858R Non-Small-Cell Lung Cancer Cell Line H3255.Cancer Res.2004;64 (20):7241-7244.
[19]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of inhibitors sensitivity in lung cancer.Cancer Sci.2007;98 (12):1817-1824.
[20]Paez JG,Janne PA,Tee JC,et al.EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy.Science 2004;304 (5676):1497.
[21]Huang SF,Liu HP,Li LH,et al.High frequency of epider-real growth factor receptor mutations with complex patterns in non-smal cel lung cancers related to gefitinib responsiveness in Taiwan.CAin CancerRes.2004,10 (24):8195-8203.
[22]误一龙。晚期NSCLC一线治疗.中国肺癌杂志,2009；12(6)：608-610.
[23]阿斯利康制药有限公司.大型临床试验ISEL研究统计分析解读.循征医学,2007：7(2)：105-106.
[24]Ciardiello F, Caputo R, Borriello G,et al.ZD1839 (iressa), an EGFR-selective tyrosine kinase inhibitor,enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int. J. Cancer. 2002;98 (3):463-469.
[25]Ciardiello F,Caputo R,Bianco R,et al.Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cell by ZD-139(Iressa),an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor.Clinical Cancer Research.2000;6 (5):2053-2063.
[26]Herbst RS,Giaccone QSchiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase III trial-intact 2.J Clin Oncol.2004;22 (5):785-794.
[27]Herbst RS,Prager D,Hemann R,et al.Tribute:a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.J Clin Oncol.2005;23 (25):5892-5899.
[28]Morelli MP,Cascone T,De Vita F,et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of Oncology.2005;16 (Suppl4):iv61-iv68.
[29]Shimoyama T,Koizumi F,Fukumoto H,et al. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer.2006;53 (1):13-21.
[30]Li T, Ling YH, Goldman ID,et al. Schedule-Dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007;13 (11):3413-3422.
[31]Brahmer JR,Gray R,et al.ECOG 4599 phase III trail of carboplatin and paclitaxel±bevacizumab:Subset analysis of survival by gender.J Clin Oncol 2005;23 (25):5892-5899.
[32]Engelman FA,Janne PA.Mechanisms of acquired resistance to epidermal growth factor recptor tyrosine kinase inhibitors in non-small cell lung cancet.Clin Cancer Res.2008;14 (10):2895-2899.
[33]Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA.1982;79 (11):3637-3640.
[34]Wu CC,Hsu HY,Liu HP,et al.Reversed Mutation Rates of KRAS and EGFR Genes in Adenocarcinoma of the Lung in Taiwan and Their Implications. Cancer. 2008; 113 (11):3199-3208.
[35]Peyssonnaux C, Provot S, Felder-Schmittbuhl MP,et al. Induction of Postmitotic Neuroretina Cell Proliferation by Distinct Ras Downstream Signaling Pathways. Mol Cell Biol.2000; 20 (19):7068-7079.
[36]Lowy DR, Willumsen BM. Function and regulation of ras.Annu Rev Biochem. 1993;62:851-891.
[37]Paumelle R, Tulasne D, Kherrouche Z, et al.Hepato-cyte growth factor/scatter factor activates the ETS1 tran-scription factor by a RAS-RAF-MEK-ERK signalingpathway.Oncogene.2002;21(15):2309-2319.
[38]Recio J A,Merlino G.Hepatocyte growth facto r/scatterfactor activates proliferation in melanoma cells throughp38 MAPK.ATF-2 and cyclin D1.Oncogene.2002;21 (7):1000-1008.
[39]Steelman LS,Pohnert SC,Shelton JG,et al.JAK/STAT,Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.Leukemia.2004; 18 (2):189-218.
[40]Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRASa re predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combinationwith erlotinib.J Clin Oncol.2005;23 (25):5900-5909.
[41]Rodenhuis S, van de Wetering ML, Mooi WJ,et al. Mutational activation of the KRAS oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med.1987;317 (15):929-935.
[42]Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res.1992;52 (9 Suppl):2665s-2669s.
[43]Gazdar A, Shigematsu H, Herz J, Minna J.Mutations and addiction to EGFR:The Achilles'heal'of lung cancers? Trends Mol Med.2004; 10 (10):481-486.
[44]Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101 (36):13306-13311.
[45]Ahrendt SA, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer.2001;92 (6):1525-1530.
[46]Pao W, Wang TY, Riely GJ,et al.KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib.PLoS Medicine.2005;2 (1):e17.
[47]Giaccone G,Ruiz MG,Chevalier TL,et al.Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer:a Phase II Study.Clin Cancer Res.2006; 12 (20):6049-6055.
[48]Marchetti A, Milella M, Felicioni L,et al.Clinical Implications of KRAS Mutations in lung Cancer Patients Treated with Tyrosine Kinase Inhibitors:An Important Role for Mutations in Minor Clones. Neoplasia.2009;11 (10):1084-1092.
[49]陆舜,虞永峰,李子明.肺癌分子靶向治疗进展.Chin J Oncol,2005; 27(11): 701-704.
[50]Pao W,Miller VA,PolitiAcquired KA,et al.Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PloS Med.2005; 2 (3):e73.
[51]Bean J, Riely GJ, Balak M,et al. Acquired Resistance to EGFR Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma. Clin Cancer Res.2008; 14 (22):7519-7525.
[52]Uramoto H, Uchiumi T, Izumi H,et al. A new mechanism for primary resistance to gefitinib in lung adenocarcinoma:the role of a novel G796A mutation in exon 20 of EGFR.Anticancer Res.2007;27 (4B):2297-2303.
[53]Balak MN,Gong Y,Riely GJ,et al.Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Clin Cancer Res.2006;12(21):6494-6501.
[54]Guo A, Villen J, Kornhauser J,et al.Signaling network assembled by oncogenic EGFR and c-Met.PNAS.2008; 105 (2):692-697.
[55]Chakravarti A,Loeffler JS,Dyson NJ.Insulin-like growth factor receptor 1 mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.Cancer Res.2002;62 (1):200-207.
[56]Jones HE,Goddard L,Gee JM,et al.Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839;Iressa) in human breast and prostate cancer cells.Endocr Relat Cancer.2004; 11 (4):793-814.
[57]Morgillo F, Woo JK, Kim ES.Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib Cancer Res 2006; 66 (20):10100-10111.
[58]You WK,McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB reports.2008; 41 (12):833-839.
[59]Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res.2005; 15 (1):49-51.
[60]Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.Met, metastasis, motility and more. Nat Rev Mol Cell Biol.2003; 4(12):915-925.
[61]Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem.2003; 88 (2):408-417.
[62]Boccaccio C,Comoglio PM.Invasive growth:a MET driven genetic programme for cancer and stem cells. Nat Rev Cancer.2006;6 (8):637-645.
[63]Ma PC,Jagadeeswaran R,Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res.2005;65 (4):1479-1488.
[64]Zucali PA,Ruiz MG,Giovannetti E,et al.Role of c-met expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.Annals of Oncology.2008; 19 (9):1605-1612.
[65]Bean J,Brennan C,Shih JY,et al.MET amplification occurs with or without T790M mutation in EGFR mutation lung tumors with acquired resistance to gefitinib or erlotinib.PNAS 2007; 104 (52):20932-20937.
[66]Martens T,Schmidt NO,Eckerich C,et al.A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.Clin Cancer Res.2006;12 (20 Pt 1):6144-6152.
[67]Zou HY,Li Q,Lee H,et al.An orally available small-molecule nihibitor of c-Met,PF-2341066,exhibits cytore-ductive antitumor efficacy through antiproliferative and antiangigenic mechanisms.Cancer Res 2007;67 (9):4408-4417.
[68]Christensen JG,Schreck R,Burrows J,et al.A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exibits Cytoreductive Antitumor Activity in Vivo. Cancer Res.2003;63 (21):7345-7355.
[69]Puri N,Ralgia R.Synergism of EGFR and c-Met pathways,cross-talk and inhibition,in non-small cell lung cancer. Journal of Carcinogenesis 2008;7(9):1-7.
[70]Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib. Hum Mol Genet.2004; 13 (24) 3029-3043.
[71]Ishikawa N, Daigo Y, Takano A,et al. Increases of Amphiregulin and Transforming Growth Factor-a in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers. Cancer Res.2005; 65:(20):9176-9184.
[72]Morgillo F, Kim WY, Kim ES,et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res.2007; 13 (9):2795-803.
[73]Uenol Y, Sakurai H, Matsuo M,et al. Selective inhibition of TNF-a-induced activation of mitogenactivated protein kinases and metastatic activities by gefitinib. British Journal of Cancer.2005;92 (9):1690-1695.
[74]Birchmeier C,Birchmeier W,Gherardi E,Vande Woude GF.Met,metastasis, motility and more.Nat Rev Mol Cell Biol.2003;4 (12):915-925.
[75]Trusolino L,Comoglio PM.Scatter-factor and semaphorin receptors:cell signalling for invasive growth. Nat Rev Cancer 2002;2 (4):289-300.
[76]Furge KA,Zhang YW,Vande Woude GF.Met receptor tyrosine kinase:enhanced signaling through adapter proteins.Oncogene.2000; 19 (49):5582-5589.
[77]Olivero M, Rizzo M, Madeddu R,et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Britsh Journal of Cancer.1996;74 (12):1862-1868.
[78]Ichimura E, Maeshima A, Nakajima T,et al.Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.Jpn J Cancer Res 1996;87 (10):1063-9.
[79]高霞,刁路明,陈洪雷等.肝细胞生长因子及其受体在非小细胞肺癌中的表达及意义.实用肿瘤杂志,2005；20(1)：17-20.
[80]刘静,王岩,杨 斌等.肝细胞生长因子在非小细胞肺癌中的表达及其意义.中国实验诊断学,2007；11(2)：155-158.
[81]Janmaat ML, Kruyt FE,Rodriguez JA,Giaccone G.Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells:Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways.Clinical Cancer Research.2003;9 (6):2316-2326.
[82]EngelmanJA,MukoharaT, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.J Clin Invest.2006; 116 (10):2695-2706.
[83]She QB,Solit D,Basso A,Moasser MM.Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling.Clinical Cancer Research. 2003;9 (12):4340-4346.
[84]Cully M,You H,Levine AJ,Mak TW.Beyond PTEN mutations:the PI3K pathway as an inetgrator of multiple inputs during tumorigenesis.Nat Rev Cancet.2006; 6 (3):184-192.
[85]Iwasaki A,Kuwahara M,Yoshinaga Y,Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothoracic Surg.2004;25 (3):443-448.
[86]Tortora G,Bianco R,Dannaro G,et al.Overcoming resistance to molecularly targeted anticancer therapies:Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.Drug Resist Update.2007; 10 (3):81-100.
[87]Ciardiello F,Bianco R,Damiano V,et al.Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.Clin Cancer Res.2000; 6(9):3739-3747.
[88]Ciardiello F,Bianco R,Caputo R,et al.Antitumor activity oa ZD6474,a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.Clin Cancer Res.2004; 10 (2):784-793.
[89]Viloria-Petit A, Crombet T,Jothy S,et al.Acquired resistance to the antitumor effect of epidermal growth factor receptor-bloking antibodies in vivo:a role for altered tumor angiogenesis.Cancer Res.2001;61 (13):5090-5101.
[2]Scagliotti GV,Selvaggi QNovello S,Hirsch FR.The biology of epidermal growth factor recptor in lung cancer.Clin Cancer Res.2004;10 (12 Pt 2):4227s-4232s.
[3]Yarden Y,Sliwkouski MX.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol.2001;2 (2):127-137.
[4]Schlessinger J.Cell signaling by receptor tyrosine kinases.Cell.2000; 103 (2) 211-225.
[5]Mendelsohn J,Baselga J.The EGF receptor family as targets for cancer therapy.Oncogene.2000; 19 (56):6550-6565.
[6]Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis.Eur JCancer.2001;37 (Suppl 4):S9-S15.
[7]Salomon DS,Brandt R,Ciardiello F,Normanno N.Epidermal growth factor-related peptides and their receptors in human malignancies.Crit Rev Oncol Hemaol.1995;19 (3):183-232.
[8]Ennis BW,Lippman ME,Dickson RB.The EGF receptor system as a target for antitumor therapy.Cancer Invest.1991;9 (5):553-562.
[9]朱岩,张晓彤,李龙芸.EGFR酪氨酸激酶域基因变异及相关蛋白表达与gefitinib治疗晚期非小细胞肺癌疗效相关性的研究进展.肺癌进展杂志,2006,4(2)：147-151.
[10]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) J Clin Oncol.2003;21 (12):2237-2246.
[11]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidetmal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Cancer Sci.2007;98 (12):1817-1824.
[12]张力.NCCN一线治疗引出的思考.中国肺癌杂志,2009,12(6)：611-614.
[13]Lynch TJ,Bel DW,Serdela R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N En J Med.2004;350 (21):2129.
[14]Paez JG,Janne PA,Tee JC,et al.EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy. Science 2004;304 (5676):1497.
[15]Pao W,Miller VA,Politi KA,et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PloS Med.2005;2 (3):e73.
[16]Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small cell lung cancer to gefitinib.N Engl J Med.2005;352 (8):786-792.
[17]Bean J,Brennan C,Shih JY,et al.MET amplification occurs with or without T790M mutation in EGFR mutation lung tumors with acquired resistance to gefitinib or erlotinib.PNAS.2007; 104 (52):20932-20937.
[18]Engelman JA, Zejnullahu K, Mitsudomi T, et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316 (5827):1039-1043.
[19]Pao W,Wang TY,Riely GJ, et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.PloS Med.2005;2 (1):e17.
[20]Giaccone QGallegos RM,Le CT,et al.Erlotinib for frontline treatment of advanced non-small cell lung cancer:a phase Ⅱ study.Clin Cancer Res.2006; 12 (20 Pt1):6049-6055.
[21]She QB,Solit D,Basso A,Moasser MM.Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.Clin Cancer Res.2003;9 (12):4340-4346.
[22]Balak MN,Gong Y,Riely GJ.et al.Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Clin Cancer Res.2006; 12(21):6494-6501.
[23]Rodenhuis S, van de Wetering ML, Mooi WJ,et al. Mutational activation of the KRAS oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med.1987;317 (15):929-935.
[24]Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res.1992;52 (9 Suppl):2665s-2669s.
[25]Gazdar A, Shigematsu H, Herz J, Minna J.Mutations and addiction to EGFR:The Achilles'heal'of lung cancers? Trends Mol Med.2004; 10 (10):481-486.
[26]Birchmeier C,Birchmeier W,Gherardi E,Vande Woude GF.Met,metastasis, motility and more.Nat Rev Mol Cell Biol.2003;4 (12):915-925.
[27]Trusolino L,Comoglio PM. Scatter-factor and semaphoring receptors:cell signalling for invasive growth. Nat Rev Cancer 2002;2 (4):289-300.
[28]Furge KA,Zhang YW,Vande Woude GF.Met receptor tyrosine kinase:enhanced signaling through adapter proteins.Oncogene.2000; 19 (49):5582-5589.
[29]Boccaccio C,Comoglio PM.Invasive growth:a MET driven genetic programme for cancer and stem cells. Nat Rev Cancer.2006;6 (8):637-645.
[30]Olivero M, Rizzo M, Madeddu R,et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Britsh Journal of Cancer.1996;74 (12):1862-1868.
[31]Ichimura E, Maeshima A, Nakajima T,et al.Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.Jpn J Cancer Res 1996;87 (10):1063-9.
[32]Namiki Y,Namiki T,Yoshida H,et al.Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839,Iressa) for dissemination pritoneal scirrhous gastric cancer.Int.J.Cancer.2006;118 (6) 1545-1555.
[33]Christensen JQSchreck R,Burrows J,et al.A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exibits Cytoreductive Antitumor Activity in Vivo. Cancer Res.2003;63 (21):7345-7355.
[34]Dong G,Lee TL,Yeh NT,et al.Metastatic squamou cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expressin,scattering and metastasis in response to hepatocyte growth factor.Oncogene.2004;23 (37) 6199-6208.
[35]Gao CF,Vande Woude GF..HGF/SF-Met signaling in tumor progression.Cell Research.2005;15 (1):49-51.
[36]Maulik G,Shrikhande A,Kijima T,et al.Role of the hepatocyte growth factor receptor,c-Met,in oncogenesis and potential for therapeutic inhibition.Cytokine Growth Factor Rev.2002; 13 (1):41-59.
[37]Comoglio PM,Giordano S,Trusolino L.Drug development of MET inhibitors: targeting oncogene addiction and expedience.Nat Rev Drug Discov.2008;7 (6) 504-516.
[38]高霞,刁路明,陈洪雷等.肝细胞生长因子及其受体在非小细胞肺癌中的表达及意义.实用肿瘤杂志,2005,20(1)：17-20.
[39]刘静,王岩,杨斌等.肝细胞生长因子在非小细胞肺癌中的表达及其意义.中国实验诊断学,2007,11(2)：155-158.
[40]Zucali PA,Ruiz MQGiovannetti E,et al.Role of c-met expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology.2008;19 (9):1605-1612.
[41]MoCubrey JA,Steelman LS,Chappell WH,et al.Role of the Raf/MEK/ERK pathway in cell growth,malignant,transformation and drug resistance.Biochim Biophys Acta.2007;1773 (8):1263-1284.
[42]Jiang BH,Liu LZ.PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta.2008;1784 (1):150-158.
[43]Haura EB, Zheng Z,Song L,et al. Activated Epidermal Growth Factor Receptor-STAT-3 Signaling Promotes Tumor Survival In vivo in Non-Small Cell Lung Cancer. Clin Cancer Res.2005;11 (23):8288-8294.
[44]Arteaga CL.Epidermal growth factor receptor dependence in human tumors:more than just expression? Oncologist.2002;7 (Sppl 4):31-39.
[45]Ritter CA, Arteaga CL.The epidermal growth factor receptortyrosine kinase:a promising therapeutic target in solid tumors. Semin Oncol.2003;30 (1 Suppl 1) 3-11.
[46]Ciardiello F,Caputo R,Bianco R,et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa),an epidermal growth factor receptor-selective tyrosine kinase inhibitor.Clin Cancer Res.2000;6 (5):2053-2063.
[47]Konishi J,Yamazaki K,Kinoshita I,et al.Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.Anticancer Res.2005;25 (1B):435-441.
[48]Birnbaum A,Ready N.Gefitinib therapy for non-small cell lung cancer.Curr Treat Options Oncol.2005;6 (1):75-81
[49]Mu XL,Li LY,Zhang XT,et al.Evaluation of safety and eficacy of gefitinib ('iressa',zd1839) as monotherapy in a series of Chinese patients with advanced non-small cell lung cancer:esperience from acompassionate-use programme.BMC Cancer.2004;4:51.
[50]Zhang XZ,Chang A.Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Int.J.Med.2008;5 (4):209-217.
[51]Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer:search and destroy. Eur J Cancer.2006;42 (1):17-23.
[52]Tracy S,Mukohara T,Hansen M,et al.Gefitinib Induces Apoptosis in the EGFRL858R Non-Small-Cell Lung Cancer Cell Line H3255.Cancer Res.2004;64 (20):7241-7244.
[53]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of inhibitors sensitivity in lung cancer. Cancer Sci.2007;98 (12):1817-1824.
[54]Huang SF,Liu HP,Li LH,et al.High frequency of epidermeal growth factor receptor mutations with complex patterns in non-smal cel lung cancers related to gefitinib responsiveness in Taiwan.Clin Cancer Res.2004;10 (24):8195-8203.
[55]Engelman FA,Janne PA.Mechanisms of acquired resistance to epidermal growth factor recptor tyrosine kinase inhibitors in non-small cell lung cancet.Clin Cancer Res.2008;14 (10):2895-2899.
[56]Chakravarti A,Loeffler JS,Dyson NJ.Insulin-like growth factor receptor 1 mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.Cancer Res.2002;62 (1):200-207.
[57]Jones HE,Goddard L,Gee JM,et al.Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839;Iressa) in human breast and prostate cancer cells.Endocr Relat Cancer.2004; 11 (4):793-814.
[58]EngelmanJA,MukoharaT,Zejnullahu K,et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.J Clin Invest.2006; 116 (10):2695-2706.
[59]Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib. Hum Mol Genet.2004; 13 (24) 3029-3043.
[60]Ishikawa N, Daigo Y, Takano A,et al. Increases of Amphiregulin and Transforming Growth Factor-a in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers. Cancer Res.2005; 65:(20):9176-9184. TGF-a
[61]Morgillo F, Kim WY, Kim ES,et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res.2007; 13 (9):2795-803.IGF-I
[62]Uenol Y, Sakurai H, Matsuo M,et al. Selective inhibition of TNF-a-induced activation of mitogenactivated protein kinases and metastatic activities by gefitinib. British Journal of Cancer.2005;92 (9):1690-1695.
[63]牛慧彦,李慧,何平.肝细胞生长因子对肺癌95D细胞系增殖和侵袭的影响。中国医学工程,2009,17(3)：164-166.
[64]Mueller KL,Hunter LA,Ethier SP,et al.Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells.Cancet Res.2008;68 (9):3314-3322.
[65]姜凯,黄志强.肝细胞生长因子和血管内皮细胞生长因子的生物学特性研究进展[J].肿瘤防治杂志,2003,10(1)：108-112.
[66]张保国,徐晋,姚乐申.恶性肿瘤患者血清中肝细胞生长因子定量测定的临床意义[J].实用医学杂志,2005,12(46)：41-47.
[67]Senguta S,Gherardi E,Sellers LA,et al.Hepatocyte growth factor/scater factor can induce angiogenesis independently of vascular endothelial growth factor[J].Arterioscler Thromb Vasc Biol.2003;23 (1):69-75.
[68]Wojta J,Kaun C,Breuss JM,et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest.1999;79 (4):427-438.
[69]Hynes NE,MacDonald G.ErbB receptors and signaling pathways in cancer.Current Opinion in Cell Biology.2009;21 (2):177-184.
[70]Ma PC,Tretiakova MS,Nallasura V,et al.Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer:implications for tumour invasion.British Journal of Cancer.2007;97 (3):368-377.
[71]Huether A,Hopfner M,Sutter AP,et al.Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chmosensitivity towards cytostatics.Journal of Hepatology.2005;43 (4):661-669.
[72]Chang GC, Hsu SL, Tsai JR,et al. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochemical Pharmacology.2004;68 (7):1453-1464.
[73]Walter KA,Hossain MA,Luddy C,et al.Scatter Factor/Hepatocyte Growth Factor Stimulation of Glioblastoma Cell Cycle Progression throuth G1 Is c-Myc Dependent and Independent of P27 Suppression,Cdk2 Activation, or E2F1-Dependent Transcription.Mol Cell Biol.2002;22 (8):2703-2715.
[74]Yu-hua Z,Wei W,Hao X,et al.Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinomal cells through MEK and PI3K signaling path ways. Chinese Medical Journal 2007;120 (9):743-748.
[75]Bonine-Summers AR,Aakre ME,Brown KA,et al.Epidermal Growth Factor Receptor Plays a Significant Role in Hepatocyte Growth Factor Mediated Biological Responses in Mammary Epithelial Cells.Cancer Biology & Therapy. 2007;6 (4):el-e10.
[76]董彤,辛晓燕.肝细胞生长因子及其受体在卵巢癌细胞中的表达[J].肿瘤与临床,2006,8(18)：541-543.
[77]Ma PC,Jagadeeswaran R,Jagadeesh S,et al.Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res.2005;65 (4):1479-1488.
[78]Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell.2003;3 (4) 347-361.
[79]Siegfried JM,Weissfeld LA, Singh-Kaw P,et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res.1997;57 (3):433-439.
[80]Sawada K,Radjabi AR, Shinomiya N,et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res.2007;67 (4):1670-1679.
[81]Masuya D,Huang C,Liu D,et al.The tumour-stromal interaction between intretumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients.British Journal of Cancer.2004;90 (8):1555-1562.
[82]Guo A, Villen J, Kornhauser J,et al.Signaling network assembled by oncogenic EGFR and c-Met. PNAS.2008; 105 (2):692-697.
[83]Tsao MS, Yang Y, Marcus A,et al.Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum Pathol. 2001;32 (1):57-65.
[84]Graham Carpenter. Employment of the Epidermal Growth Factor Receptor in Growth Factor-independent Signaling Pathways. The Journal of Cell Biology 1999;146 (4):697-702.
[85]Riedemann J,Sohail M,Macaulay VM.Dual silencing of the EGF and type I IGF receptors suggests dominance of IGF signaling in human breast cancer cells.Biochem Biophys Res Commun.2007;355 (3):700-706.
[86]Riedemann J,Takiguchi M,Sohil M,Macaulay VM.The EGF receptor interacts with the type I IGF receptor and regulates its stability. Biochem Biophys Res Commun2007;355 (3):707-714.
[87]Jo MJ, Stolz DB, Esplen JE,et al. Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells.THE JOURNAL OF BIOLOGICAL CHEMISTRY.2000;275 (12):8806-8811.
[88]Pai R, Nakamura T, Moon WS,et al.Prostaglandins promote colon cancer cell invasion;signaling by cross-talk between two distinct growth factor receptors. FASEB J.2003; 17 (12); 1640-1647.
[89]Reznik TE,Sang Y,Ma Y,et al.Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.Mol Cancer Res.2008;6 (1) 139-150.
[90]Puri N,Ralgia R.Synergism of EGFR and c-Met pathways,cross-talk and inhibition,in non-small cell lung cancer. Journal of Carcinogenesis.2008;7 (9):1-7.
[91]Wen J,Matsumoto K,Taniura N,et al.Inhibition of colon cancer growth and meastasis by NK4 gene repetitive delivery in mice.Biochem Biothys Res Commun.2007;358 (1):117-123.
[92]Martens T,Schmidt NO,Eckerich C,et al.A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.Clin Cancer Res 2006; 12 (20Pt 1):6144-6152.
[93]Zou HY,Li Q,Lee H,et al.An orally available small-molecule nihibitor of c-Met, PF-2341066,exhibits cytore-ductive antitumor efficacy through antiproliferative and antiangigenic mechanisms.Cancer Res.2007;67 (9):4408-4417.
[1]Bunn PA Jr,Kelly K.New chemotherapeutic agents prolong survival and improve quality of life in non-smll cell lung cancer:a review of the literature and futrre directions.Clin Cancer Res.1998;4 (5):1087-1100.
[2]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidetmal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Cancer Sci.2007;98 (12):1817-1824.
[3]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) .J Clin Oncol.2003;21 (12):2237-2246.
[4]MoCubrey JA,Steelman LS,Chappell WH,et al.Role of the Raf/MEK/ERK pathway in cell growth,malignant,transformation and drug resistance.Biochim Biophys Acta.2007;1773 (8):1263-1284.
[5]Jiang BH,Liu LZ.PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta.2008; 1784 (1):150-158.
[6]Haura EB, Zheng Z,Song LX,et al. Activated Epidermal Growth Factor Receptor-STAT-3 Signaling Promotes Tumor Survival In vivo in Non-Small Cell Lung Cancer. Clin Cancer Res 2005; 11 (23):8288-8294.
[7]Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis.Eur J Cancer.2001;37 (Suppl 4):S9-S15.
[8]Salomon DS,Brandt R,Ciardiello F,Normanno N.Epidermal growth factor-related peptides and their receptors in human malignancies.Crit Rev Oncol Hemaol.1995;19 (3):183-232.
[9]Arteaga CL.Epidermal growth factor receptor dependence in human tumors:more than just expression? Oncologist 2002;7 (14):31-39.
[10]Ciardiello F,Caputo R,Bianco R,et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa),an epidermal growth factor receptor-selective tyrosine kinase inhibitor.Clin Cancer Res.2000;6
(5):2053-2063.
[11]Konishi J,Yamazaki K,Kinoshita I,et al.Analysis of the response and toxicity to gefitinib of non-small cell lung cancer. An ticancer Res.2005;25 (1B):435-441.
[12]Birnbaum A,Ready N.Gefitinib therapy for non-small cell lung cancer.Curr Treat Options Oncol.2005;6 (1):75-81.
[13]Mu XL,Li LY,Zhang XT,et al.Evaluation of safety and eficacy of gefitinib ('iressa',zd1839) as monotherapy in a series of Chinese patients with advanced non-small cell lung cancenesperience from acompassionate-use programme.BMC Cancer.2004;4:51.
[14]朱岩,张晓彤,李龙芸.EGFR酪氨酸激酶域基因变异及相关蛋白表达与gefitinib治疗晚期非小细胞肺癌疗效相关性的研究进展.肺癌进展杂志,2006;4(2)：147-151.
[15]张力。NCCN一线治疗引出的思考.中国肺癌杂志,2009；12(6)：611-614.
[16]Lynch TJ,Bel DW,Serdela R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N En J Med.2004;350 (21):2129.
[17]Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer:search and destroy. Eur J Cancer.2006;42 (1):17-23.
[18]Tracy S,Mukohara T,Hansen M,et al.Gefitinib Induces Apoptosis in the EGFRL858R Non-Small-Cell Lung Cancer Cell Line H3255.Cancer Res.2004;64 (20):7241-7244.
[19]Mitsudomi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene and related genes as determinants of inhibitors sensitivity in lung cancer.Cancer Sci.2007;98 (12):1817-1824.
[20]Paez JG,Janne PA,Tee JC,et al.EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy.Science 2004;304 (5676):1497.
[21]Huang SF,Liu HP,Li LH,et al.High frequency of epider-real growth factor receptor mutations with complex patterns in non-smal cel lung cancers related to gefitinib responsiveness in Taiwan.CAin CancerRes.2004,10 (24):8195-8203.
[22]误一龙。晚期NSCLC一线治疗.中国肺癌杂志,2009；12(6)：608-610.
[23]阿斯利康制药有限公司.大型临床试验ISEL研究统计分析解读.循征医学,2007：7(2)：105-106.
[24]Ciardiello F, Caputo R, Borriello G,et al.ZD1839 (iressa), an EGFR-selective tyrosine kinase inhibitor,enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int. J. Cancer. 2002;98 (3):463-469.
[25]Ciardiello F,Caputo R,Bianco R,et al.Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cell by ZD-139(Iressa),an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor.Clinical Cancer Research.2000;6 (5):2053-2063.
[26]Herbst RS,Giaccone QSchiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase III trial-intact 2.J Clin Oncol.2004;22 (5):785-794.
[27]Herbst RS,Prager D,Hemann R,et al.Tribute:a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.J Clin Oncol.2005;23 (25):5892-5899.
[28]Morelli MP,Cascone T,De Vita F,et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of Oncology.2005;16 (Suppl4):iv61-iv68.
[29]Shimoyama T,Koizumi F,Fukumoto H,et al. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer.2006;53 (1):13-21.
[30]Li T, Ling YH, Goldman ID,et al. Schedule-Dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007;13 (11):3413-3422.
[31]Brahmer JR,Gray R,et al.ECOG 4599 phase III trail of carboplatin and paclitaxel±bevacizumab:Subset analysis of survival by gender.J Clin Oncol 2005;23 (25):5892-5899.
[32]Engelman FA,Janne PA.Mechanisms of acquired resistance to epidermal growth factor recptor tyrosine kinase inhibitors in non-small cell lung cancet.Clin Cancer Res.2008;14 (10):2895-2899.
[33]Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA.1982;79 (11):3637-3640.
[34]Wu CC,Hsu HY,Liu HP,et al.Reversed Mutation Rates of KRAS and EGFR Genes in Adenocarcinoma of the Lung in Taiwan and Their Implications. Cancer. 2008; 113 (11):3199-3208.
[35]Peyssonnaux C, Provot S, Felder-Schmittbuhl MP,et al. Induction of Postmitotic Neuroretina Cell Proliferation by Distinct Ras Downstream Signaling Pathways. Mol Cell Biol.2000; 20 (19):7068-7079.
[36]Lowy DR, Willumsen BM. Function and regulation of ras.Annu Rev Biochem. 1993;62:851-891.
[37]Paumelle R, Tulasne D, Kherrouche Z, et al.Hepato-cyte growth factor/scatter factor activates the ETS1 tran-scription factor by a RAS-RAF-MEK-ERK signalingpathway.Oncogene.2002;21(15):2309-2319.
[38]Recio J A,Merlino G.Hepatocyte growth facto r/scatterfactor activates proliferation in melanoma cells throughp38 MAPK.ATF-2 and cyclin D1.Oncogene.2002;21 (7):1000-1008.
[39]Steelman LS,Pohnert SC,Shelton JG,et al.JAK/STAT,Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.Leukemia.2004; 18 (2):189-218.
[40]Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRASa re predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combinationwith erlotinib.J Clin Oncol.2005;23 (25):5900-5909.
[41]Rodenhuis S, van de Wetering ML, Mooi WJ,et al. Mutational activation of the KRAS oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med.1987;317 (15):929-935.
[42]Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res.1992;52 (9 Suppl):2665s-2669s.
[43]Gazdar A, Shigematsu H, Herz J, Minna J.Mutations and addiction to EGFR:The Achilles'heal'of lung cancers? Trends Mol Med.2004; 10 (10):481-486.
[44]Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101 (36):13306-13311.
[45]Ahrendt SA, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer.2001;92 (6):1525-1530.
[46]Pao W, Wang TY, Riely GJ,et al.KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib.PLoS Medicine.2005;2 (1):e17.
[47]Giaccone G,Ruiz MG,Chevalier TL,et al.Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer:a Phase II Study.Clin Cancer Res.2006; 12 (20):6049-6055.
[48]Marchetti A, Milella M, Felicioni L,et al.Clinical Implications of KRAS Mutations in lung Cancer Patients Treated with Tyrosine Kinase Inhibitors:An Important Role for Mutations in Minor Clones. Neoplasia.2009;11 (10):1084-1092.
[49]陆舜,虞永峰,李子明.肺癌分子靶向治疗进展.Chin J Oncol,2005; 27(11): 701-704.
[50]Pao W,Miller VA,PolitiAcquired KA,et al.Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PloS Med.2005; 2 (3):e73.
[51]Bean J, Riely GJ, Balak M,et al. Acquired Resistance to EGFR Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma. Clin Cancer Res.2008; 14 (22):7519-7525.
[52]Uramoto H, Uchiumi T, Izumi H,et al. A new mechanism for primary resistance to gefitinib in lung adenocarcinoma:the role of a novel G796A mutation in exon 20 of EGFR.Anticancer Res.2007;27 (4B):2297-2303.
[53]Balak MN,Gong Y,Riely GJ,et al.Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Clin Cancer Res.2006;12(21):6494-6501.
[54]Guo A, Villen J, Kornhauser J,et al.Signaling network assembled by oncogenic EGFR and c-Met.PNAS.2008; 105 (2):692-697.
[55]Chakravarti A,Loeffler JS,Dyson NJ.Insulin-like growth factor receptor 1 mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.Cancer Res.2002;62 (1):200-207.
[56]Jones HE,Goddard L,Gee JM,et al.Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839;Iressa) in human breast and prostate cancer cells.Endocr Relat Cancer.2004; 11 (4):793-814.
[57]Morgillo F, Woo JK, Kim ES.Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib Cancer Res 2006; 66 (20):10100-10111.
[58]You WK,McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB reports.2008; 41 (12):833-839.
[59]Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res.2005; 15 (1):49-51.
[60]Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.Met, metastasis, motility and more. Nat Rev Mol Cell Biol.2003; 4(12):915-925.
[61]Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem.2003; 88 (2):408-417.
[62]Boccaccio C,Comoglio PM.Invasive growth:a MET driven genetic programme for cancer and stem cells. Nat Rev Cancer.2006;6 (8):637-645.
[63]Ma PC,Jagadeeswaran R,Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res.2005;65 (4):1479-1488.
[64]Zucali PA,Ruiz MG,Giovannetti E,et al.Role of c-met expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.Annals of Oncology.2008; 19 (9):1605-1612.
[65]Bean J,Brennan C,Shih JY,et al.MET amplification occurs with or without T790M mutation in EGFR mutation lung tumors with acquired resistance to gefitinib or erlotinib.PNAS 2007; 104 (52):20932-20937.
[66]Martens T,Schmidt NO,Eckerich C,et al.A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.Clin Cancer Res.2006;12 (20 Pt 1):6144-6152.
[67]Zou HY,Li Q,Lee H,et al.An orally available small-molecule nihibitor of c-Met,PF-2341066,exhibits cytore-ductive antitumor efficacy through antiproliferative and antiangigenic mechanisms.Cancer Res 2007;67 (9):4408-4417.
[68]Christensen JG,Schreck R,Burrows J,et al.A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exibits Cytoreductive Antitumor Activity in Vivo. Cancer Res.2003;63 (21):7345-7355.
[69]Puri N,Ralgia R.Synergism of EGFR and c-Met pathways,cross-talk and inhibition,in non-small cell lung cancer. Journal of Carcinogenesis 2008;7(9):1-7.
[70]Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib. Hum Mol Genet.2004; 13 (24) 3029-3043.
[71]Ishikawa N, Daigo Y, Takano A,et al. Increases of Amphiregulin and Transforming Growth Factor-a in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers. Cancer Res.2005; 65:(20):9176-9184.
[72]Morgillo F, Kim WY, Kim ES,et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res.2007; 13 (9):2795-803.
[73]Uenol Y, Sakurai H, Matsuo M,et al. Selective inhibition of TNF-a-induced activation of mitogenactivated protein kinases and metastatic activities by gefitinib. British Journal of Cancer.2005;92 (9):1690-1695.
[74]Birchmeier C,Birchmeier W,Gherardi E,Vande Woude GF.Met,metastasis, motility and more.Nat Rev Mol Cell Biol.2003;4 (12):915-925.
[75]Trusolino L,Comoglio PM.Scatter-factor and semaphorin receptors:cell signalling for invasive growth. Nat Rev Cancer 2002;2 (4):289-300.
[76]Furge KA,Zhang YW,Vande Woude GF.Met receptor tyrosine kinase:enhanced signaling through adapter proteins.Oncogene.2000; 19 (49):5582-5589.
[77]Olivero M, Rizzo M, Madeddu R,et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Britsh Journal of Cancer.1996;74 (12):1862-1868.
[78]Ichimura E, Maeshima A, Nakajima T,et al.Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.Jpn J Cancer Res 1996;87 (10):1063-9.
[79]高霞,刁路明,陈洪雷等.肝细胞生长因子及其受体在非小细胞肺癌中的表达及意义.实用肿瘤杂志,2005；20(1)：17-20.
[80]刘静,王岩,杨 斌等.肝细胞生长因子在非小细胞肺癌中的表达及其意义.中国实验诊断学,2007；11(2)：155-158.
[81]Janmaat ML, Kruyt FE,Rodriguez JA,Giaccone G.Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells:Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways.Clinical Cancer Research.2003;9 (6):2316-2326.
[82]EngelmanJA,MukoharaT, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.J Clin Invest.2006; 116 (10):2695-2706.
[83]She QB,Solit D,Basso A,Moasser MM.Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling.Clinical Cancer Research. 2003;9 (12):4340-4346.
[84]Cully M,You H,Levine AJ,Mak TW.Beyond PTEN mutations:the PI3K pathway as an inetgrator of multiple inputs during tumorigenesis.Nat Rev Cancet.2006; 6 (3):184-192.
[85]Iwasaki A,Kuwahara M,Yoshinaga Y,Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothoracic Surg.2004;25 (3):443-448.
[86]Tortora G,Bianco R,Dannaro G,et al.Overcoming resistance to molecularly targeted anticancer therapies:Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.Drug Resist Update.2007; 10 (3):81-100.
[87]Ciardiello F,Bianco R,Damiano V,et al.Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.Clin Cancer Res.2000; 6(9):3739-3747.
[88]Ciardiello F,Bianco R,Caputo R,et al.Antitumor activity oa ZD6474,a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.Clin Cancer Res.2004; 10 (2):784-793.
[89]Viloria-Petit A, Crombet T,Jothy S,et al.Acquired resistance to the antitumor effect of epidermal growth factor receptor-bloking antibodies in vivo:a role for altered tumor angiogenesis.Cancer Res.2001;61 (13):5090-5101.